Abstract | CONTEXT: OBJECTIVES: To evaluate a newly developed mouse monoclonal uroplakin II antibody (BC21) in urothelial carcinoma and to compare it with previously developed mouse monoclonal uroplakin III (BC17 and AU1). DESIGN: RESULTS: BC21, BC17, and AU1 demonstrated sensitivities in urothelial carcinoma of the bladder of 79% (44 of 56), 55% (31 of 56) (P = .002), and 34% (19 of 56) (P < .001), respectively. Subsequently, the increased staining sensitivity and intensity of BC21, compared with BC17, was validated in a larger study (134 of 174; 77% and 94 of 174; 54%, respectively) (P < .001). BC21 was found to be highly specific when evaluated in various normal and neoplastic tissues, including prostatic and renal carcinomas. CONCLUSIONS: The mouse monoclonal uroplakin II antibody (BC21) demonstrated superior sensitivity and specificity in urothelial carcinoma, compared with uroplakin III (BC17 and AU1), suggesting its advantages in the differential diagnosis of urothelial carcinoma and in the detection of tumors of unknown origin.
|
Authors | Laura L Hoang, David E Tacha, Weimin Qi, Charlie Yu, Ryan E Bremer, Joseph Chu, Thomas S Haas, Liang Cheng |
Journal | Archives of pathology & laboratory medicine
(Arch Pathol Lab Med)
Vol. 138
Issue 7
Pg. 943-9
(Jul 2014)
ISSN: 1543-2165 [Electronic] United States |
PMID | 24978921
(Publication Type: Comparative Study, Evaluation Study, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Biomarkers, Tumor
- UPK2 protein, human
- UPK3A protein, human
- Uroplakin II
- Uroplakin III
|
Topics |
- Animals
- Antibodies, Monoclonal, Murine-Derived
- Antibody Specificity
- Biomarkers, Tumor
(immunology, metabolism)
- Blotting, Western
- Carcinoma, Transitional Cell
(diagnosis, metabolism)
- Female
- Humans
- Immunohistochemistry
- Male
- Mice
- Pregnancy
- Tissue Distribution
- Urinary Bladder Neoplasms
(diagnosis, metabolism)
- Uroplakin II
(immunology, metabolism)
- Uroplakin III
(immunology, metabolism)
- Urothelium
(metabolism)
|